Characteristics of patients receiving nonmyeloablative transplants
| . | CMV-HR (n = 52) . | CMV-IR (n = 8) . | CMV-LR (n = 41) . |
|---|---|---|---|
| Age (y) median (range) | 46.5 (25-59) | 41 (21-50) | 42 (18-59) |
| Sex (male/female) | 33/19 | 6/2 | 29/12 |
| Disease | |||
| AML/ALL/MDS | 7/0/0 | 1/0/0 | 1/2/2 |
| CML/CLL | 4/3 | 1/0 | 0/2 |
| NHL/HD | 19/5 | 2/2 | 19/8 |
| Myeloma | 14 | 2 | 7 |
| Previous transplants | 13 | 4 | 17 |
| Donor type | |||
| Matched family | 36 | 5 | 26 |
| Matched unrelated | 10 | 2 | 12 |
| Mismatched unrelated | 6 | 1 | 3 |
| Days to neutrophil > 0.5 × 109/L median (range) | 13 (8-45) | 11 (11-18) | 12 (9-25) |
| Acute GVHD | |||
| None | 38 | 6 | 24 |
| Grades I-II de novo/after DLI | 4/2 | 1/0 | 9/3 |
| Grades III-IV de novo/after DLI | 2/6 | 0/1 | 2/3 |
| . | CMV-HR (n = 52) . | CMV-IR (n = 8) . | CMV-LR (n = 41) . |
|---|---|---|---|
| Age (y) median (range) | 46.5 (25-59) | 41 (21-50) | 42 (18-59) |
| Sex (male/female) | 33/19 | 6/2 | 29/12 |
| Disease | |||
| AML/ALL/MDS | 7/0/0 | 1/0/0 | 1/2/2 |
| CML/CLL | 4/3 | 1/0 | 0/2 |
| NHL/HD | 19/5 | 2/2 | 19/8 |
| Myeloma | 14 | 2 | 7 |
| Previous transplants | 13 | 4 | 17 |
| Donor type | |||
| Matched family | 36 | 5 | 26 |
| Matched unrelated | 10 | 2 | 12 |
| Mismatched unrelated | 6 | 1 | 3 |
| Days to neutrophil > 0.5 × 109/L median (range) | 13 (8-45) | 11 (11-18) | 12 (9-25) |
| Acute GVHD | |||
| None | 38 | 6 | 24 |
| Grades I-II de novo/after DLI | 4/2 | 1/0 | 9/3 |
| Grades III-IV de novo/after DLI | 2/6 | 0/1 | 2/3 |
AML indicates acute myeloid leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukaemia; HD, Hodgkin disease; NHL, non-Hodgkin disease.
The differences between these subgroups were not significant (P > .05).